Coeptis TherapeuticsCOEP
COEP
About: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Employees: 7
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4.27% less ownership
Funds ownership: 4.3% [Q3] → 0.03% (-4.27%) [Q4]
60% less funds holding
Funds holding: 15 [Q3] → 6 (-9) [Q4]
81% less capital invested
Capital invested by funds: $300K [Q3] → $56.3K (-$243K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for COEP.
Financial journalist opinion
Based on 3 articles about COEP published over the past 30 days
Neutral
GlobeNewsWire
3 weeks ago
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.
Neutral
GlobeNewsWire
3 weeks ago
COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors
Neutral
Business Wire
3 weeks ago
NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan
CENTENNIAL, Colo.--(BUSINESS WIRE)--NUBURU, Inc. (NYSE: BURU), a leading innovator in high-power and high-brightness industrial blue laser technology announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP), an innovative provider of artificial intelligence and robotics solutions. This collaboration is a pivotal component of NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficie.
Neutral
GlobeNewsWire
1 month ago
COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology
Neutral
GlobeNewsWire
1 month ago
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
Neutral
GlobeNewsWire
1 month ago
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
Neutral
GlobeNewsWire
1 month ago
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups
WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents.
Neutral
PRNewsWire
1 month ago
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
WEXFORD, Pa. , Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million.
Neutral
PRNewsWire
2 months ago
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value WEXFORD, Pa. , Jan. 30, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy.
Neutral
PRNewsWire
2 months ago
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth WEXFORD, Pa. , Jan. 23, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the expansion of its technological initiatives to include cutting-edge artificial intelligence and innovative blockchain solutions.
Charts implemented using Lightweight Charts™